Marwan Sabbagh, MD, shares strategies for the differential diagnosis of dementia, along with implications of new developments like the advent of blood tests for the presence of brain amyloid plaques.
A genetic variant of the tumor necrosis factor receptor 2 pathway is associated with modulation of indicators of Alzheimer’s disease severity and slower functional decline. These cohort study findings hold promise for development of targeted therapies.
Most therapies in development for Alzheimer’s are focused on changing disease biology, with targets ranging from amyloid pathology to inflammation. A leader of our clinical trials program shares an update on drug development and diagnostics.
Two new clinical trials are testing the hypothesis that the dual mechanistic actions of this anticancer drug can reduce pathological biomarkers and improve cognition in early-stage AD.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Interdisciplinary researchers are focusing a multitude of coordinated investigations on how chronic inflammation contributes to AD — and the resulting therapeutic implications.
With the exception of oral anticoagulation treatment for atrial fibrillation, there is little evidence that pharmacologic or nonpharmacologic interventions slow the onset or progression of Alzheimer disease.
For the first time, this imaging tracer will be used in an attempt to detect neuroinflammation in the living brain in the setting of Parkinson’s and Alzheimer’s diseases.